as declared in digitaljournal
Immunotherapy drug is a game changer for cancer
Immunotherapy drug is a game changer for cancer
By By Tim Sandle 7 hours ago in Science Study results presented at the European Cancer Congress about a new immunotherapy drug for cancer have been described as "a game changer", based on the clinical trail evidence.Nearly 40% of pts with resected early-stage NSCLC had signs of tumor regression after neoadjuvant nivolumab #ESMO16 https://t.co/sXSJWvtm6p — OncLive.com (@OncLive) October 8, 2016 Some types of HPV cause changes in the cells of the cervix or to the lining of the mouth and throat (an effect called dysplasia.)The changed cells have an increased risk of becoming cancerous.In addition, a second study has found that by combining nivolumab with a second drug shrank tumors in advanced kidney cancer patients.
as well reuters
No silver lining in failed Bristol cancer drug trial
No silver lining in failed Bristol cancer drug trial
A trader passes by a screen displaying the tickers symbols for Bristol-Myers Squibb and Intelsat, Ltd. on the floor at the New York Stock Exchange, April 25, 2013.REUTERS/Brendan McDermidCOPENHAGEN Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.Some analysts had speculated the study would at least show Opdivo worked in a subset of lung cancer patients with a biomarker that should make them more receptive to immunotherapy, but there was no sign of this.Bristol first announced the trial failure in August, since when its shares have fallen by around a quarter, but experts have been waiting eagerly to learn exactly what went wrong and see if something might be salvaged from the setback.
furthermore irishexaminer
New drug hailed a 'game changer' for cancer patients
New drug hailed a 'game changer' for cancer patients
An immunotherapy drug could soon offer new hope to patients with currently untreatable head and neck cancers.Nivolumab was hailed a potential "game changer" after it was found to extend the lives of relapsed patients who had run out of therapy options.After a year of treatment, 36% of trial patients treated with the drug were still alive compared with 17% of those given standard chemotherapy.Patients with advanced head and neck cancers resistant to chemotherapy are notoriously difficult to treat and generally survive less than six months.
No comments:
Post a Comment